Floatz logo

Tetrahydrouridine

Previously Treated Myelodysplastic Syndromes

City of Hope Medical CenterSmall moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Previously Treated Myelodysplastic Syndromes cohort.

Asset / SponsorPhaseRating
Cediranib
M.D. Anderson Cancer Center
Phase 3BBB
Temsirolimus
National Cancer Institute (NCI)
Phase 2B
1-235-TUMOR NECROSIS FACTOR RECEPTOR (HUMAN) FUSION PROTEIN WITH 236-467-IMMUNOGLOBULIN G1 (HUMAN .GAMMA.1-CHAIN FC FRAGMENT), DIMER
Children's Oncology Group
Phase 2B
Semaxanib
National Cancer Institute (NCI)
Phase 1/2CCC
Montanide Isa 51
National Cancer Institute (NCI)
Phase 1/2CCC

View all 15 →

Same molecule, other indications

Tetrahydrouridine is also rated in:

urinary bladder neoplasmDormant
B
Indicative ·
59 / 100
View asset →
head and neck neoplasmDormant
B
Indicative ·
58 / 100
View asset →
lung neoplasmDormant
CCC
Indicative ·
55 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →